Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer

• Published in: World journal of gastroenterology : WJG Vol. 26; no. 19; pp. 2388 - 2402
• Main Authors: Li, Zheng-Yan, Wang, Xiao-Dong, Li, Mou, Liu, Xi-Jiao, Ye, Zheng, Song, Bin, Yuan, Fang, Yuan, Yuan, Xia, Chun-Chao, Zhang, Xin, Li, Qian
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 21.05.2020
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy - standards; Capecitabine - pharmacology; Capecitabine - therapeutic use; Chemotherapy, Adjuvant - methods; Female; Humans; Intestinal Mucosa; Magnetic Resonance Imaging - methods; Magnetic Resonance Imaging - standards; Male; Middle Aged; Multimodal Imaging - methods; Multimodal Imaging - standards; Neoadjuvant Therapy - methods; Nomograms; Oxaliplatin - pharmacology; Oxaliplatin - therapeutic use; Predictive Value of Tests; Proctectomy; Rectal Neoplasms - diagnosis; Rectal Neoplasms - pathology; Rectal Neoplasms - therapy; Rectum - diagnostic imaging; Rectum - drug effects; Reference Standards; Retrospective Studies; Retrospective Study; ROC Curve; Tomography, X-Ray Computed - methods; Tomography, X-Ray Computed - standards; Treatment Outcome; Neoadjuvant chemotherapy; Computed tomography; Magnetic resonance imaging; Rectal cancer; Radiomics
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v26.i19.2388

Neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer (LARC); however, evaluation of treatment response to neoadjuvant chemotherapy is still challenging. To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for LARC. This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography (CT) and magnetic resonance imaging (MRI) before neoadjuvant chemotherapy between October 2016 and June 2019. Histopathological findings were used as the reference standard for pathological response. Patients were randomly divided into a training set ( = 70) and a validation set ( = 48). The performance of different models based on CT and MRI, including apparent diffusion coefficient (ADC), dynamic contrast enhanced T1 images (DCE-T1), high resolution T2-weighted imaging (HR-T2WI), and imaging features, was assessed by using the receiver operating characteristic curve analysis. This was demonstrated as area under the curve (AUC) and accuracy (ACC). Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the nomogram. Eighty out of 118 patients (68%) achieved a pathological response. For an individual radiomics model, HR-T2WI performed better (AUC = 0.859, ACC = 0.896) than CT (AUC = 0.766, ACC = 0.792), DCE-T1 (AUC = 0.812, ACC = 0.854), and ADC (AUC = 0.828, ACC = 0.833) in the validation set. The imaging performance for extramural venous invasion detection was relatively low in both the training (AUC = 0.73, ACC = 0.714) and validation (AUC = 0.578, ACC = 0.583) sets. The multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set, and an AUC of 0.93 and ACC of 0.875 in the validation set. For the clinical radiomics nomogram, good agreement was found between the nomogram prediction and actual observation. A multi-modal nomogram using traditional imaging features and radiomics of preoperative CT and MRI adds accuracy to the prediction of treatment outcome, and thus contributes to the personalized selection of neoadjuvant chemotherapy for LARC.